Literature DB >> 12149199

Mixed chimera status of 12 patients with Wiskott-Aldrich syndrome (WAS) after hematopoietic stem cell transplantation: evaluation by flow cytometric analysis of intracellular WAS protein expression.

Koji Yamaguchi1, Tadashi Ariga, Masafumi Yamada, David L Nelson, Ryouji Kobayashi, Chie Kobayashi, Yasushi Noguchi, Yasuhiko Ito, Kenji Katamura, Yoshihisa Nagatoshi, Satoshi Kondo, Hiroyuki Katoh, Yukio Sakiyama.   

Abstract

Wiskott-Aldrich syndrome (WAS) is caused by defects in the WAS protein (WASP) gene on the X chromosome. We previously reported that flow cytometric analysis of intracellular WASP expression (FCM-WASP) was useful in the diagnosis of WAS in patients and carriers. In this study, we applied FCM-WASP to evaluate the mixed chimera (MC) status of 12 WAS patients who underwent hematopoietic stem cell transplantation (HST). After HST, donor- and recipient-derived peripheral blood mononuclear cells (PBMCs) could be distinguished easily with this method, since the donor cells were WASP(bright), whereas the defective recipient cells were WASP(dim). Furthermore, with use of 2-color FCM-WASP, the MC status could be characterized by cell lineage. Six of the 12 patients with WAS were found to have MC status after HST, whereas others had complete chimera status. MC status was observed in every cell lineage examined. However, among PBMCs, recipient cells were most commonly observed in the monocyte population. Finally, to investigate the naive/memory status of donor and recipient T cells in these patients, 3-color FCM-WASP using anti-CD45RA or CD45RO was performed. We found that, in contrast to WASP(bright) T cells, most WASP(dim) T cells remained naive (CD45RA(+)/RO(-)) more than a year after HST. No imbalance in the ratio of naive to memory T cells was observed in WAS patients before HST. We conclude that FCM-WASP is a potentially useful method for clinical follow-up of WAS patients who have undergone HST. Our findings may also have important implications for the role of WASP during hematopoietic development.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12149199     DOI: 10.1182/blood-2002-01-0211

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

1.  Mutational analysis of the WASP gene in 2 Korean families with Wiskott-Aldrich syndrome.

Authors:  Eun-Kyeong Jo; Takeshi Futatani; Hirokazu Kanegane; Takeo Kubota; Young-Ho Lee; Jin-A Jung; Chang-Hwa Song; Jeong-Kyu Park; Shigeaki Nonoyama; Toshio Miyawaki
Journal:  Int J Hematol       Date:  2003-07       Impact factor: 2.490

2.  WASP confers selective advantage for specific hematopoietic cell populations and serves a unique role in marginal zone B-cell homeostasis and function.

Authors:  Lisa S Westerberg; Miguel A de la Fuente; Fredrik Wermeling; Hans D Ochs; Mikael C I Karlsson; Scott B Snapper; Luigi D Notarangelo
Journal:  Blood       Date:  2008-09-04       Impact factor: 22.113

3.  Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome.

Authors:  Salima Hacein-Bey Abina; H Bobby Gaspar; Johanna Blondeau; Laure Caccavelli; Sabine Charrier; Karen Buckland; Capucine Picard; Emmanuelle Six; Nourredine Himoudi; Kimberly Gilmour; Anne-Marie McNicol; Havinder Hara; Jinhua Xu-Bayford; Christine Rivat; Fabien Touzot; Fulvio Mavilio; Annick Lim; Jean-Marc Treluyer; Sébastien Héritier; Francois Lefrère; Jeremy Magalon; Isabelle Pengue-Koyi; Géraldine Honnet; Stéphane Blanche; Eric A Sherman; Frances Male; Charles Berry; Nirav Malani; Frederic D Bushman; Alain Fischer; Adrian J Thrasher; Anne Galy; Marina Cavazzana
Journal:  JAMA       Date:  2015-04-21       Impact factor: 56.272

Review 4.  Hematopoietic cell transplantation for Wiskott-Aldrich syndrome: advances in biology and future directions for treatment.

Authors:  Sung-Yun Pai; Luigi D Notarangelo
Journal:  Immunol Allergy Clin North Am       Date:  2010-05       Impact factor: 3.479

5.  Phenotypic and genotypic correction of WASP gene mutation in Wiskott-Aldrich syndrome by unrelated cord blood stem cell transplantation.

Authors:  Young-Ho Lee; Yeon-Jung Lim; Su-Ah Shin; Chang-Hwa Song; Eun-Kyeong Jo; Jin-A Jung; Ha-Baik Lee
Journal:  J Korean Med Sci       Date:  2009-07-30       Impact factor: 2.153

6.  Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome.

Authors:  Alessandro Aiuti; Luca Biasco; Samantha Scaramuzza; Francesca Ferrua; Maria Pia Cicalese; Cristina Baricordi; Francesca Dionisio; Andrea Calabria; Stefania Giannelli; Maria Carmina Castiello; Marita Bosticardo; Costanza Evangelio; Andrea Assanelli; Miriam Casiraghi; Sara Di Nunzio; Luciano Callegaro; Claudia Benati; Paolo Rizzardi; Danilo Pellin; Clelia Di Serio; Manfred Schmidt; Christof Von Kalle; Jason Gardner; Nalini Mehta; Victor Neduva; David J Dow; Anne Galy; Roberto Miniero; Andrea Finocchi; Ayse Metin; Pinaki P Banerjee; Jordan S Orange; Stefania Galimberti; Maria Grazia Valsecchi; Alessandra Biffi; Eugenio Montini; Anna Villa; Fabio Ciceri; Maria Grazia Roncarolo; Luigi Naldini
Journal:  Science       Date:  2013-07-11       Impact factor: 47.728

7.  Evidence for long-term efficacy and safety of gene therapy for Wiskott-Aldrich syndrome in preclinical models.

Authors:  Francesco Marangoni; Marita Bosticardo; Sabine Charrier; Elena Draghici; Michela Locci; Samantha Scaramuzza; Cristina Panaroni; Maurilio Ponzoni; Francesca Sanvito; Claudio Doglioni; Marie Liabeuf; Bernard Gjata; Marie Montus; Katherine Siminovitch; Alessandro Aiuti; Luigi Naldini; Loïc Dupré; Maria Grazia Roncarolo; Anne Galy; Anna Villa
Journal:  Mol Ther       Date:  2009-03-03       Impact factor: 11.454

Review 8.  Clinical Features, Cancer Biology, Transplant Approach and Other Integrated Management Strategies for Wiskott-Aldrich Syndrome.

Authors:  Smitha Hosahalli Vasanna; Maria A Pereda; Jignesh Dalal
Journal:  J Multidiscip Healthc       Date:  2021-12-23

Review 9.  Wiskott-Aldrich syndrome: diagnosis, current management, and emerging treatments.

Authors:  David Buchbinder; Diane J Nugent; Alexandra H Fillipovich
Journal:  Appl Clin Genet       Date:  2014-04-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.